Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA

References

• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386. ​​​​
   PubMed Web of Science ®Google Scholar
• Kowal SL, Dall TM, Chakrabarti R, et al. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311–318.
   PubMed Web of Science ®Google Scholar
• Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80–89.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1–136.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001;56(11 Suppl 5):S1–S88.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–1071.
   PubMed Web of Science ®Google Scholar
• Stocchi F. The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opin Pharmacother. 2006;7(10):1399–1407.
   PubMedGoogle Scholar
• Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983–995.
   PubMed Web of Science ®Google Scholar
• Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20(6):726–733.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Tolosa E, Hernandez B, et al. The patient card questionnaire to identify wearing-off in parkinson disease. Clin Neuropharmacol. 2007;30(5):266–275.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Lyons KE. Levodopa-related wearing-off in Parkinson’s disease: identification and management. Curr Med Res Opin. 2009;25(4):841–849.
   PubMed Web of Science ®Google Scholar
• Antonini A, Martinez-Martin P, Chaudhuri RK, et al. Wearing-off scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(12):2169–2175.
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–458.
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20(2):224–230.
   PubMed Web of Science ®Google Scholar
• Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80(9):800–809.
   PubMed Web of Science ®Google Scholar
• Michael J. Fox Foundation. Report: Capturing and Elevating the Patient Voice. [Last accessed October 2016]. Available at https://www.michaeljfox.org/foundation/news-detail.php?capturing-and-elevating-the-patient-voice (2014).
   Google Scholar
• Salat D, Tolosa E. Levodopa in the treatment of Parkinson’s disease: current status and new developments. J Parkinsons Dis. 2013;3(3):255–269.
   PubMedGoogle Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S2–41.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15.
   PubMed Web of Science ®Google Scholar
• Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009;8(10):929–937.
   PubMed Web of Science ®Google Scholar
• Crispo JA, Fortin Y, Thibault DP, et al. Trends in inpatient antiparkinson drug use in the USA, 2001-2012. Eur J Clin Pharmacol. 2015;71(8):1011–1019.
   PubMed Web of Science ®Google Scholar
• Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson’s disease. Mov Disord. 2011;26(4):587–598.
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–237.
   PubMed Web of Science ®Google Scholar
• Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004;4:CD004554.
   Google Scholar
• European Medicines Agency. Tasmar (tolcapone) EPAR summary for the public. 2014. EMA/388409/2014. ​​​​
   Google Scholar
• Muller T. Catechol-o-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–174.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346–356.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20(12):1335–1340.
   PubMed Web of Science ®Google Scholar
• Lewitt P, Friedman H, Giladi N, et al. Accordion pill carbidopa/levodopa for improved treatment of advanced Parkinson’s disease symptoms [abstract]. Mov Disord. 2012;27(Suppl 1):408.
   Google Scholar
• LeWitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease. Mov Disord. 2014;29(1):75–82.
   PubMed Web of Science ®Google Scholar
• Giladi N, Caraco Y, Gurevich T, et al. Pharmacokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson’s disease (PD) patients with motor fl uctuations: results of a Phase IIa dose finding study (Abstract). Mov Disord. 2015;30(Suppl):1.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord. 2016;31(9):1356–1365.
   PubMed Web of Science ®Google Scholar
• Kiss LE, Soares-da-Silva P. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility. J Med Chem. 2014;57(21):8692–8717.
   PubMed Web of Science ®Google Scholar
• Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53(8):3396–3411.
   PubMed Web of Science ®Google Scholar
• Palma PN, Bonifacio MJ, Loureiro AI, et al. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem. 2012;33(9):970–986.
   PubMed Web of Science ®Google Scholar
• Almeida L, Rocha JF, Falcao A, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet. 2013;52(2):139–151.
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Sutcliffe JS, Torrao L, et al. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology. 2014;77:334–341.
   PubMed Web of Science ®Google Scholar
• BIAL Data on File. 2016. ​​​​
   Google Scholar
• Rocha JF, Falcao A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014;70(9):1059–1071.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Ferreira JJ, Falcao A, et al. Effect of 3 single-dose regimens of Opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev. 2016;5(3):232–240.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ongentys. Assessment Report. EMA/343011/2016.
   Google Scholar
• Rocha JF, Santos A, Falcao A, et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol. 2014;70(3):279–286.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Rocha JF, Falcao A, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol. 2015;22(5):815–825.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2015;15:154–165.
   PubMed Web of Science ®Google Scholar
• Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations: a randomized, controlled trial with open-label extension. JAMA Neurol. 2017 Feb 1;74(2):197-206. ​​​​
   Google Scholar
• Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov Disord. 2011;26(5):813–818.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Gordon MF, Mizuno Y, et al. Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis. 2014;467131:2014.
   Google Scholar
• Poewe W. The role of COMT inhibition in the treatment of Parkinson’s disease. Neurology. 2004;62(1 Suppl 1):S31–8.
   PubMed Web of Science ®Google Scholar
• Ferreira J, Lees A, Santos A, et al. Efficacy of opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations: analysis of pooled phase III studies [abstract]. Mov Disord. 2015;30(Suppl 1):221.
   PubMed Web of Science ®Google Scholar
• Ferreira J, Lees A, Santos A, et al. One-year follow-up of opicapone’s efficacy and safety in patients with Parkinson’s disease and motor fluctuations (BIPARK I). Parkinsonism & Related Disord. 2015;22:e100.
   Google Scholar
• Ferreira J, Lees AJ, Tolosa E, et al. Switching double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I [abstract]. Mov Disord. 2016;31(suppl 2). ​​​​
   Google Scholar
• Pinto R, l’Hostis P, Patat A, et al. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2015;4(6):454–462.
   PubMed Web of Science ®Google Scholar
• Ferreira J, Lees AJ, Lopes N, et al. Evaluation of the safety and tolerability of opicapone in the treatment of Parkinson’s disease and motor fluctuations: analysis of pooled phase III studies. Eur J Neurol. 2015;22(Suppl. 1):611.
   Google Scholar
• Lees AJ, Ferreira J, Lopes N, et al. Efficacy and safety of opicapone in patients over 70 years with Parkinson’s disease and motor fluctuations [abstract]. Mov Disord. 2015;30(Suppl 1):258.
   Google Scholar
• Ongentys. Summary of Product Characteristics. 2016. ​​​​
   Google Scholar
• Lopes N, Ferreira J, Lees AJ, et al. Hepatic safety of opicapone in Parkinson’s disease patients [abstract]. Mov Disord. 2015;30(Suppl 1):263.
   Google Scholar
• Tuite P, Thomas C, Ruekert L, et al. Parkinson’s disease: A guide to patient care. New York: Springer Publishing Company LLC; 2009.
   Google Scholar
• Lopes N, Ferreira J, Lees A, et al. Exploratory efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinson’s disease [abstract]. Mov Disord. 2015;30(Suppl 1):264.
   Google Scholar
• Hely MA, Morris JG, Traficante R, et al. The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67(3):300–307.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71(7):474–480.
   PubMed Web of Science ®Google Scholar
• Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196–1205.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.
   PubMed Web of Science ®Google Scholar
• Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756–1760.
   PubMed Web of Science ®Google Scholar